C'est William K. Schmidt, Vice President, Clinical Development de CrystalGenomics qui va développer le sujet en mettant en avant son produit en Phase IIa.
NicOx n'interviendra pas. Bien dommage qu'ils ne soient pas présent pour défendre leur (notre !) beefsteak, le Naproxcinod !
Next Generation NSAID de Crystalgenomics
Indications: Osteoarthritis, rheumatoid arthritis, CNS diseases (e.g. Alzheimer’s, Huntington’s, etc), and colon cancer.
Current status: Phase IIa Clinical Trial in EU has been completed and further development plans are ongoing.
CG100649 is a next generation NSAID which inhibits COX-2 in the
inflammatory joint, but not in the cardiovascular and gastrointestinal systems. Thus, CG100649 is highly efficacious in the control of inflammation and pain without showing typical side effects of other NSAIDs have shown. Such tissue specific inhibition has been demonstrated in the preclinical and clinical studies. Recently, a phase IIa clinical trial in EU has been completed showing the superiority of CG100649 in efficacy over placebo. There were no withdrawals due to lack of efficacy. There were no drug-related serious adverse events, and no indication of a negative effect on heart function, ECG profiles or blood pressure. Moreover, no evidence of gastrointestinal bleeding was found during the study.
Plan: Further Clinical Development through Partnering.